

John M. McCall, Ph.D.

Responsibilities

- Board Chair, Reveragen. Founded Reveragen with Eric Hoffman and Kanneboyina Nagaraju. Drugs for Duchenne. Vamorolone is currently in P2b.
- Vice President Chemistry, Reveragen
- Foundation advisory boards: IRSF, PPMD
- President, PharMac LLC, March 2005 to present. Consultant in areas of drug discovery, project management, project evaluation, and research organization.
- Member, multiple business and science advisory boards
- Past position In Pfizer: Vice President Pfizer Global Research and Development, Site Head for Chicago area, member Pfizer Global Technology Board, member Steering Committee Global Informatics, member Chemistry Globalization Technology Working Group. 2003-2005
- Past position in heritage Pharmacia: Global Vice President Discovery Chemistry with responsibility for Structural and Analytical Chemistry, Medicinal and Combinatorial Chemistry, Computational Chemistry, Cheminformatics. Global staff of 570. 2000-2003
- Past position in heritage Pharmacia&Upjohn and Pharmacia: Global Vice President Discovery Chemistry (94-98), Vice President Discovery Chemistry (98-2000, Chemistry Director Sweden (99-2000)
- Past position in heritage Upjohn: Group Leader CVDR Research (1979-81), Associate Director Hypersensitivity Research (1978), Director CNS Research (1987-1990), Vice President of Chemistry (1990-94)

Contact Information

Telephone: 941 268 6393. Skype 941 306 3939

Email: JMMCCAL2@gmail.com

Address: John M. McCall, PharMac LLC, PO Box 2253, Boca Grande, FL, 33921

Active advisory boards and retained consultancy: Reveragen, Hotspot (start 2017), Imago (2012), NINDS Blueprint Steering Committee (2011), NIH NeuroNEXT (2013), Expansion (2017), Quartet (2014), Rodin (2016), Rheostat (2017), Nimbus (2019), Psychogenics (2008), Reaction Biology (2005), Tuberous Sclerosis Alliance (2016), Rett Foundation (2009), Disc (2019), Quench(2018), Lycera (2010), University of Nebraska Medical Center (2012)

Inactive advisory boards and retained consultancy: AdmetRx, Receptors LLC, NaturNorth, International Drug Discovery Institute, Avaant, Charley's Fund, Terpenoid Therapeutics, Cortex, Tobira, ShanaRx, Xenon, University of Rochester, Zafgen,, Biovitrum, AzoRx, Biostrategy Advisors, Gore, Michigan State University, Nanomite, PharmaDirections, Tripos, XB Transmed, Kinentia Bioscience, Neuromed, Zalicus, Lilly PD2 Review Panel, Cardero, Prothelia ,Synergenics, Tourettttes Task Force, CeeTox SAB, University of Rochester HIV dementia project, Emerald, Numerate, UCB, Verseon

Focus Of Work

- **Reveragen BioPharma**
 - Chair, Board of Directors
 - VP responsible for patents, formulation and chemistry

- **PharMac LLC**
 - Scientific Advisory Boards, Boards, Consulting in area of drug discovery, venture projects, team building, and leadership training.
 - Steering Committees NIH NeuroNext and Blueprint programs.
 - Chair NINDS spinal muscular atrophy drug discovery development team
 - NINDS Study Section
- **Pfizer**
 - Outsourcing strategies
 - Career planning for Pfizer executives
 - Design and implementation of technology and chemistry globalization
 - Create ROI model for drug discovery process
 - Transfer of PHA projects to Pfizer. Closure of four Chicago facilities
 - Transfer of chemistry technologies to Pfizer.
 - Facilitating restructuring of cheminformatics in Pfizer
- **Pharmacia**
 - Transition of chemistry from a purely local to a global organization. One portfolio resourcing
 - Resource optimization in structure based drug design
 - ChemLink: a unifying, multifunctional, and powerful informatics system that includes various data organization and manipulation tools
 - Compound infrastructure in Discovery Technology (compound collection, Haystack, centralized HTS)
 - Combichem and library design strategies
 - High throughput crystallography
 - 600,000 compound screening library
 - Aggressive recruiting worldwide
 - Coordinated outsourcing program

Awards, Editorial Positions

Industrial Awards: The Upjohn Award (1985), Chemistry Symposium Award (1991) Upjohn Science and Medicine Award (1994)

Education

Postdoctoral Experience

Harvard University (1970-72)
 Professor R.B. Woodward
 Synthesis of Vitamin B12

Graduate Experience

University of Wisconsin (1966-1970)
 Ph.D. in Organic Chemistry, October 1970
 Major Professor: Dr. H.E. Zimmerman

PUBLICATIONS

1. Eric Hoffman; Benjamin Schwartz; Laurel Mengle-Gaw; Edward Smith; Diana Castro; Jean Mah; Craig McDonald; Nancy Kuntz; Richard Finkel; Michela Guglieri; Mar Tulinius; Yoram Nevo; Monique Ryan; Richard Webster; Andrea Smith; Lauren Morgenroth; Adrienne Arrieta; Maya Shimony; Catherine Siener; Mark Jaros; Phil Shale; John McCall; Kanneboyina Nagarajui; John van den Anker; Laurie Conklin; Avital Cnaan; Heather Gordish-Dressman; Jesse Damsker; Paula

Clemens. Vamorolone trial in Duchenne muscular dystroph shows dose-related improvement of muscle function. *Neurology*. Accepted May 2019.

2. Eric Hoffman; Benjamin Schwartz; Laurel Mengle-Gaw; Edward Smith; Diana Castro; Jean Mah; Craig McDonald; Nancy Kuntz; Richard Finkel; Michela Guglieri; Mar Tulinius; Yoram Nevo; Monique Ryan; Richard Webster; Andrea Smith; Lauren Morgenroth; Adrienne Arrieta; Maya Shimony; Catherine Siener; Mark Jaros; Phil Shale; John McCall; Kanneboyina Nagarajui; John van den Anker; Laurie Conklin; Avital Cnaan; Heather Gordish-Dressman; Jesse Damsker; Paula Clemens. Vamorolone retains efficacy and reduces safety concerns of glucocorticoid drugs, *Science Translational Medicine*, Submitted Oct 2018
3. Laurie S. Conklin, Jesse M. Damsker, William J. Jusko, Benjamin Schwartz, Laurel Mengle-Gaw, Edward C. Smith, Jean Mah, Michela Guglieri, Yoram Nevo Nancy Kuntz, Craig McDonald, Mar Tulinius, Monique Ryan, Richard Webster, Diana Castro, Richard S. Finkel Andrea Smith, Lauren P. Morgenroth, Adrienne Arrieta, Maya Shimony, Mark Jaros, Phil Shale, John M. McCall, Kanneboyina Nagaraju, John van den Anker, Leanne Ward, Alexandra Ahmet, Michaelyn R. Cornish, Eric P. Hoffman, Paula R. Clemens: "Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug". *Pharmacological Research*, Accepted for publication Sept 2018
4. Eric P. Hoffman, Valerie Riddle, Maxime A. Siegler, Daniel Dickerson, Miroslav Backonja, William G. Kramer, Kanneboyina Nagaraju, Heather Gordish Dressman, Jesse M. Damsker, John M. McCall. Phase 1 trial of vamorolone, a first in class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. *Steroids* (Elsevier). April 2018.
5. Eric P. Hoffman, PhD^{1,2*}; Valerie Riddle, MD¹; Daniel Dickerson, MD³; Miroslav Backonja, MD³; William G. Kramer, PhD⁴; Nancy M. Warzecha⁵; Kanneboyina Nagaraju, DVM PhD^{1,2}; Jesse M. Damsker, PhD¹; John McCall, PhD¹. Phase 1 clinical trial of a first-in-class dissociative steroid, vamorolone, shows wide-spread improvements in pharmacodynamic safety. *Journal: Science Translational Medicine*. In press.
6. Kanneboyina Nagaraju, Eric P. Hoffman, Paula R. Clemens, Kate Bushby, Michela Guglieri, Jesse Damsker, Valerie Riddle, Daniel Dickerson, Miroslav Backonja, William G. Kramer, Ben Schwartz, John McCall. Clinical Development of a Dissociative Steroidal Anti-inflammatory: Vamorolone. *Neuromuscular Disorders/ International WMS Congress*. Oct 4-8, 2016. Barcelona.
7. Jesse M. Damsker, Ph.D.; Laurie S. Conklin, M.D.; Soheil Sadri, M.S.; Blythe C. Dillingham, B.S.; Karuna Panchapakesan; Christopher R. Heier, Ph.D.; John M. McCall, Ph.D.; Anthony D. Sandler, M.D., "VBP15, a novel dissociative steroid compound, reduces NF-κB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis", *Inflammation Research*, 2016
8. Emma Heslop, Cristina Csimma, Volker Straub, John McCall, Kanneboyina Nagaraju, Kathryn Wagner, Didier Caizergues, Rudolf Korinthenberg, Kevin M Flanigan, Petra Kaufmann, Elizabeth McNeil, Jerry Mendell, Sharon Hesterlee, Dominic Wells and Kate Bushby, "The TREAT-NMD Advisory Committee for Therapeutics (TACT): An innovative de-risking model to foster orphan drug development", *Orphanet Journal of Rare Diseases*, 2015
9. Blythe C. Dillingham, Susan M. Knoblach, Gina M. Many, Amanda M. Mullen, Brennan T. Harmon, Christopher R. Heier, Luca Bello, John M. McCall, Eric P. Hoffman, Edward M. Conner, Kanneboyina Nagaraju, Erica K.M. Reeves, and Jesse M. Damsker. "VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis". Submitted to *Journal of Immunology*, March 2014
10. Chris Heier, Jesse Damsker, Qing Yu, Blythe Dillingham, Tony Huynh, Jack Van Der Meulen, Arpana Sali,

Brittany Miller, Aditi Phadke, Luana Scheffer, James Quinn, Kathleen Tatern, Sarah Jordan, Sherry Dadgar, Olga Rodriguez, Chris Albanese, Michael Calhoun, Heather Gordish, Jyoti Jaiswal, Edward Connor, John McCall, Eric Hoffman, Erica Reeves, Kanneboyina Nagaraju. "VBP15, a novel anti-inflammatory and membrane stabilizer, improves muscular dystrophy without side effects". *EMBO Molecular Medicine*. 2013. 5: 1-17.

11. Reeves EK, Hoffman EP, Nagaraju K, Damsker JM, McCall JM. VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid. *Bioorg Med Chem*. 2013 Apr 15;21(8):2241-9
12. Damsker JM, Dillingham BC, Rose MC, Balsley MA, Heier CR, Watson AM, Stemmy EJ, Jurjus RA, Huynh T, Tatem K, Uaesoontrachoon K, Berry DM, Benton AS, Freishtat RJ, Hoffman EP, McCall JM, Gordish-Dressman H, Constant SL, Reeves EK, Nagaraju K. VBP15, a Glucocorticoid Analogue, Is Effective at Reducing Allergic Lung Inflammation in Mice. *PLoS One*. 2013 May 7;8(5)
13. Hoffman EP, Reeves E, Damsker J, Nagaraju K, McCall JM, Connor EM, Bushby K. Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy. *Phys Med Rehabil Clin N Am*. 2012 Nov;23(4):821-8.
14. Baudy AR*, Reeves EK*, Damsker JM, Heier C, Garvin LM, Dillingham BC, McCall J, Rayavarapu S, Wang Z, Vandermeulen JH, Sali A, Jahnke V, Duguez S, DuBois D, Rose MC, Nagaraju K, Hoffman EP. Δ -9,11 modification of glucocorticoids dissociates nuclear factor- κ B inhibitory efficacy from glucocorticoid response element-associated side effects. *J Pharmacol Exp Ther*. 2012 Oct;343(1):225-32..
15. Story C. Landis, Susan G. Amara, Khusru Asadullah, Chris P. Austin⁴, Robi Blumenstein, Eileen W. Bradley, Ronald G. Crystal, Robert B. Darnell, Robert J. Ferrante, Howard Fillit, Robert Finkelstein, Marc Fisher, Howard E. Gendelman, Robert Golub, John L. Goudreau, Robert A. Gross, Amelie K. Gubitz, Sharon E. Hesterlee, David W. Howells, John Huguenard, Katrina Kelner, Walter Koroshetz, Dimitri Krainc, Stanley E. Lazic, Michael S. Levine, Malcolm Macleod, John M. McCall, Richard T. Moxley III, Kalyani Narasimhan, Linda J. Noble, Steve Perrin, "A Call for Transparent Reporting to Optimize the Predictive Value of Preclinical Research, *Nature*, October 11, 2012
16. John D. Porter¹, Oswald Steward²⁹, Ellis Unger³⁰, Ursula Utz¹ & Shai D. Silberberg¹ Andreas Baudy, Erica Reeves, Jesse Damsker, Christopher Heier, Lindsay Garvin, John McCall, Sree Rayavarapu, Zuyi Wang, Jack Vandermeulen, Srpana Sali, Vanessa Jahnke, Stephanie Duguez, Debra DuBois, Mary Rose, Kanneboyina Nagaraju, Eric Hoffman. "[Delta]-9,11 modifications of glucocorticoids dissociate NF- κ B inhibitory efficacy from GRE-associated side effects", *Journal of Pharmacology and Experimental Therapeutics*, accepted June 2012
17. Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs, editors Michael J. Barratt and Donald E. Frail, Wiley 2012, pp418-426, chapter by Jill Panetta, John M McCall. "Repositioning drugs for Polycystic Kidney Disease (PKD): Perspectives from the Polycystic Kidney Disease Foundation".
18. Amelie K. Gubitz; John M. McCall; Keith D. Barnes; Sangeeta P. Chitnis; Svetlana V. Dobritsa; Chris L. Lorson; Monique A. Lorson; Michele M. Luche; Graham Johnson; John Lippert; Virginia B. Mattis; Nick Mayhew; Amy R. Noe; Sabina I. Robinson; James A. Romano Jr.; Donna L. Romero; Jill Heemskerk, "The SMA Project: A Progress Report", Families of SMA Conference, June, 2009
19. Jill Heemskerk, Amelie Gubitz, John McCall. "Chemical Optimization of Indoprofen for the Treatment of SMA". 13th Annual International SMA Research Group Meeting (Cincinnati; June 18th to 20th).
20. Steve Street, Martin Mackay, and John McCall, "Risk Reduction in Drug Discovery and Development", *Current Topics in Medicinal Chemistry*, 2005, 5:1087-1090.
21. Martin Mackay and John McCall, "The Technology Revolution. Is it Payback Time?", Drug Discovery, Business Briefing: Pharmatech, 2004: 27-39.

22. D.E. Epps and J.M. McCall, "Physical and Chemical Mechanisms of the Antioxidant Action of Tirilazad Mesylate" in Handbook of Novel Antioxidants. Antioxid. Health Dis. (1997), 4:95-137
23. J.M. McCall, The discovery and pharmacology of tirilazad mesylate in Cell Biology of Trauma ed J.J. Lemasters, C. Oliver, CRC Press (Boca Raton, London, Tokyo), 1995:105-114.
24. D.E. Epps, T.J. Knechtel, O. Baczynskyj, D. Decker, D.M. Guido, S.E. Buxser, W.R. Mathews, S.L. Buffenberger, B.S. Lutzke, J.M. McCall, L.K. Oliver, F.J. Kezdy, "Tirilazad mesylate protects stored erythrocytes against osmotic fragility." Chemistry and Physics of Lipids, 1994, 74: 163-174.
25. K.L. Linseman, B.S. Lutzke, A.R. Cazars, J.M. McCall and D.E. Epps, "Kinetic evaluation of lipophilic inhibitors of lipid peroxidation in dilinoleoylphosphatidylcholine liposomes", Free Radical Biology and Medicine, 1994. 17:587-596.
26. J.M. McCall and J.A. Panetta, "Reactive Oxygen: Recent Therapeutic Intervention Strategies", Immunopharmacology of Free Radical Species, Academic Press, Eds: David Blake and Paul Wineyard. Published 1994. pp263-277.
27. E.D. Hall, J.M. McCall, E.D. Means, "Therapeutic Potential of the Lazaroids in Acute CNS Trauma, Ischemia, and Subarachnoid Hemorrhage", Advances in Pharmacology, Vol 28, 221-268. edited by J.T. August, M.W. Anders, F. Murad, J.T. Coyle, Academic Press, 1994.
28. J.M. McCall, "The discovery and pharmacology of tirilazad mesylate." JEUR, 1993, Vol/Iss/Pg. 6/2 (91-95).
29. E.D. Hall and J.M. McCall, "Lazaroids: Potent Inhibitors of Iron-Dependent Lipid Peroxidation for Neurodegenerative Disorders", Key Topics in Brain Research, ed. P. Riederer and M. Youdim, Springer, Vienna and New York. Submitted. Publication expected 10/93.
30. E.D. Hall and J.M. McCall, "Lazaroids: Antioxidant Action", Oxygen Radicals in Biological Systems, Part C: A volume of Methods in Enzymology, ed. L.Packer, Academic Press, Orlando, Florida. 1994, V234, pp.548-555.
31. K.L. Linseman, P. Larson, J.M. Braugher, J.M. McCall, "Iron initiated tissue oxidation: Lipid peroxidation, vitamin E destruction and protein thiol oxidation inhibited by a novel antioxidant, U-78517F", Biochemical Pharmacology, 45: 1477-82 (1993).
32. J.M. McCall and J.A. Panetta, "Traumatic and Ischemia/Reperfusion Injury to the CNS", Annual Reports in Medicinal Chemistry, Volume 27, section editor J.M. McCall, editor Jim Bristol, 1992.
33. K.L. Linseman and J.M. McCall, "The Effects of U78517F in Iron Time Course Vitamin E, TBARS and Sulfhydryl Assays in Rat Brain Homogenate", The Toxicologist, 12(1): 74 (1992).
34. E.D. Hall, J.M. Braugher, J.M. McCall, "Antioxidant Effects in Brain and Spinal Cord Injury", Journal of Neurotrauma, 9 (Supp1), S165 (1992).
35. D.K. Anderson, E.D. Hall, J.M. Braugher, J.M. McCall, E.D. Means, "Effect of Delayed Administration of U74006F on Functional Outcome Following Experimental Spinal Cord Injury", Journal of Neurotrauma, 8 (1991), 187-192.
36. E.D. Hall, J.M. Braugher, J.M. McCall, "Role of oxygen radicals in stroke: effects of the 21-aminosteroids, a novel class of antioxidants", Prog.Clin.Biol.Res., 361:351-62 (1990).
37. E.D. Hall, J.M. Braugher, J.M. McCall, "Role of Oxygen Radicals in Stroke: Effects of the 21-Aminosteroids: A Novel Class of Antioxidants" in Current and Future Trends in Anticonvulsant, Anxiety and Stroke Therapy, editors B.S. Meldrum and M. Williams, Wiley, p. 351 (1990).

38. J.A. Tamara, M.C. Hernandez Baro, L.H. Toledo-Pereyra, E.D. Hall, J.M. McCall, "Advanced En El Manejo De La Lesion De Isquemia/Reperfusion, Con Referencia A Los 21-Aminoesteroides, Rev. Fac. Med. UNAM, Submitted 1990.
39. J.M. McCall, J.A. Panetta, E.J. Jacobsen, "Acute Ischemic and Traumatic Injury to the CNS", Annual Reports in Medicinal Chemistry, section editor J.M. McCall, editor Jim Bristol, 1990.
40. E.D. Hall, K.E. Pazara, A.H. Tang, P.M. Ho, M.F. Piercey, W.E. Hoffmann, J.M. Braughler, J.M. McCall, "21-Aminosteroids, Limiting the Extent of Damage After Ischemia", New Drug Strategies in the Prevention and Treatment of Stroke, ed. C. Rose, Smith-Gordon Publishers, London, 1990.
41. R.V.W. Dimlich, P.A. Tornheim, R.M. Kindel, E.D. Hall, J.M. McCall, "Effects of a 21-Aminosteroid (U74006F) on Cerebral Metabolites and Edema after Severe Experimental Head Trauma", Advances in Neurology, 1990 (52), 365-375.
42. E.J. Jacobsen, J.M. McCall, D.E. Ayer, F.J. VanDoornik, J.R. Palmer, K.L. Belonga, J.M. Braughler, E.D. Hall, D.J. Houser, M.A. Krook, T.A. Runge, "Novel 21-aminosteroids which inhibit iron-dependent lipid peroxidation and protect against central nervous system trauma", J. Med. Chem., 1990 (33), 1145-1151.
43. J.M. McCall, "A New Class of 21-Aminosteroids which are Useful for Stroke and Trauma: The Lazaroids", chapter in Steroids in Diseases of the Central Nervous System, ed. R. Capildeo, Wiley and Sons, Sussex, July 1989, 69-82.
44. J.M. Braughler, E.D. Hall, E.J. Jacobsen, J.M. McCall and E.D. Means, "The 21-Aminosteroids: Potent Inhibitors of Lipid Peroxidation for the Treatment of Central Nervous System Trauma and Ischemia, CIPS (Correlates in Pharmacstructures), 1989 (Vol 14), 143-152.
45. E.D. Hall, J.M. Braughler, J.M. McCall, "New Pharmacological Treatments of Acute Spinal Cord Trauma", Journal of Neurotrauma, 1988 (5), 81-89].
46. D.K. Anderson, J.M. Braughler, E.D. Hall, T.R. Waters, J.M. McCall, E.D. Means, "Effects of treatment with U74006F on neurological outcome following experimental spinal cord injury", Journal of Neurosurgery, 1988 (69), 562-567.
47. M. Gall, J.M. McCall, R.E. TenBrink, P.F. VonVoigtlander and J.S. Mohrland, "Aryl Formamidines with Antinociceptive properties," Journal of Medicinal Chemistry, 1988 (31), 1816.
48. E.D. Hall, P.A. Yonkers, J.M. McCall, J.M. Braughler, "Effects of the 21-aminosteroid U74006F on experimental head injury in mice", J. Neurosurg, 1988 (68), 456-461.
49. D.K. Anderson, E.D. Means, T.R. Waters, J.M. Braughler, E.D. Hall, J.M. McCall, "Evaluation of Membrane Stabilizing Compounds for the Treatment of Acute Experimental Spinal Cord Injury", Progress in Research (American Paralysis Association, Issue 18, 1987), 6.
50. J.M. McCall, J.M. Braughler, E.D. Hall, "A New Class of Compounds for Stroke and Trauma: Effects of 21-Aminosteroids on Lipid Peroxidation", Acta Anaesthesiologica Belgica (Text of oral presentation at First Antwerp International Trauma Symposium, November 25-27, 1987)'.
(Text of oral presentation at First Antwerp International Trauma Symposium, November 25-27, 1987).
51. J.M. McCall, J.M. Braughler, E.D. Hall, "Lipid Peroxidation and the Role of Oxygen Radicals in CNS Injury", Acta Anaesthesiologica Belgica (Text of oral presentation at First Antwerp International Trauma Symposium, November 25-27, 1987).
52. R.A. Lahti, M.M. Mickelson, K.S. Jodelis and J.M. McCall, "Comparative Neuroanatomical Distribution of the Opioid Kappa and Mu-Delta Receptors in Guinea Pig Brain," European Journal of Pharmacology, 1989 (166), 563-566.

53. E.D. Hall, P.A. Yonkers, J.M. McCall and J.M. Braughler, "Enhancement of Neurological Recovery and Survival in Experimental Head Injury by the 21-Aminosteroid U74006F, A Novel and Potent Inhibitor of Iron Dependent Lipid Peroxidation," *Journal of Neurosurgery*, 1988 (68), 362.
54. E.D. Hall, P.A. Yonkers and J.M. McCall, "Attenuation of Hemorrhagic Shock by the 21-Aminosteroid U74006F", *European Journal of Pharmacology*, 1988 (147), 299-303.
55. J.M. Braughler, J.F. Pregenzer, R.L. Chase, L.A. Duncan, E.J. Jacobsen and J.M. McCall, "Novel 21-Amino Steroids as Potent Inhibitors of Iron-Dependent Lipid Peroxidation," *J. Biological Chemistry*, 1987 (262), 10438-10440.
56. E.D. Hall, J.M. McCall, R.L. Chase, P.A. Yonkers and J.M. Braughler, "A Non-Glucocorticoid Steroid Analog of Methylprednisolone Duplicates its high dose pharmacology in models of CNS trauma and Neuronal Membrane Damage", *Journal of Pharmacology and Experimental Therapeutics*, 1987(242), 137-142.
57. W.H. Darlington, L. Baczynskyj, S.A. Mizesak, T.A. Scahill, L.G. Dring, J.M. McCall and J. Szmuszkovicz, "Isolation, Identification and Synthesis of a Metabolite of Tazadolene Succinate," *Drug Design and Delivery*, 1987, p.225 (vol. 1).
58. R.A. Lahti, M.M. Mickelson, J.M. McCall and P.F. VonVoigtlander, "3H-U-69,593 - A Highly Selective Ligand for the Kappa Opioid Receptor," *European Journal of Pharmacology*, 1985 (109), 281-284.
59. J.M. McCall, R.E. TenBrink, B.V. Kamdar, L.L. Skaletzky, S.C. Perricone, R.C. Piper and P.J. Delehanty, "7-Trifluoromethyl-4-Aminoquinoline Hypotensives: Novel Peripheral Sympatholytics," *J. Med. Chem.*
60. V.H. Sethy and J.M. McCall, "High-Affinity (3H)-Dexoxadrol Binding to Rat Brain Membranae," *Drug Development Research*, 4, 635-645 (1984).
61. V.H. Sethy and J.M. McCall, "Use of (3H)-Dexoxadrol for Labelling Phencyclidine Binding Sites," *Pharmacologist*, 1984, 26:178.
62. J.M. McCall, J.W. Aiken, C.G. Chidester, D.W. DuCharme and M.G. Wendling, "Pyrimidine and Triazine 3-Oxide Sulfates: A New Family of Vasodilators," *J. Med. Chem.*, 1983, 26, 1791-1793.
63. G.A. Johnson, K.J. Barsuhn, J.M. McCall, "A Minoxidil Sulfate, a metabolite of minoxidil", *Drug Metab. Dispos.* 11:507-508 (1983).
64. G.A. Johnson, K.J. Barsuhn and J.M. McCall, "Sulfation of Minoxidil by Liver Sulfotransferase, *Biochem. Pharmacology* 31, No. 18, pp. 2949 (1982).
65. J.M. McCall, R.B. McCall, J. Orley, S.J. Humphrey, and M.G. Wendling, "Tetrahydro-2-benzoxepines: A Novel Family of Hypotensives," *J. Med. Chem.* 24, 64 (1981).
66. R.E. TenBrink and J.M. McCall, "The Synthesis of 1-Haloalkyl-1,3,4,5-Tetrahydro-2-Benzoxepines," *J. Het. Chem.* 18, 821 (1981).
67. J.M. McCall, R.E. TenBrink, H. Johnson, "1-(Ethoxyamino)methyl-1,3,4,5-tetrahydro-7,8-dimethoxy-2-benzoxepines: A new class of anti-anaphylactic agents," *J. Med. Chem.* 23, 1058 (1980).
68. J.M. McCall, B.V. Kamdar, and D. Kloosterman, "Cyanoimine Chemistry: New Routes to Pyrimidines and Pyrimidine Diones," *Synthesis*, 1980, 123.
69. J.M. McCall, B.V. Kamdar, and D. Kloosterman, "Cyanoimine Chemistry: New Routes to Pyrimidinones and (Carbonylimino) iminopropanamides." *J. Org. Chem.* 44, 1562 (1979).

70. J.M. McCall, R.E. TenBrink, B.V. Kamdar, C. Chidester, "The Preparation and Stereochemistry of 1-chloroethyl-4-methyl-6,7-dimethylisochroman," J. Het. Chem. 16, 363 (1979).
71. J.M. McCall and R.E. TenBrink, "3-Amino-3-cyaniminopropionitriles: Useful Precursors for 2-Chloro-4,6-diamino and 2,4,6-triaminopyrimidines," Synthesis, 1978, 673.
72. J.M. McCall, R.E. TenBrink, M.E. Royer, and H. Ko, "The Reaction of 2,4-Diamino-6-piperidinopyrimidine 3-Oxide with Acid Anhydrides," J. Het. Chem. 15, 1529 (1978).
73. M.E. Royer, H. Ko, T.J. Gilbertson, J.M. McCall, K.T. Johnson, and R. Stryd, "Radioimmunoassay of Minoxidil in Human Serum," J. Pharm. Sc., 66, 3924 (1977).
74. J.M. McCall, R.E. TenBrink, and J.J. Ursprung, "A New Approach to Tri-aminopyrimidine N-oxides," J. Org. Chem. 40, 3304 (1975).
75. J.M. McCall and R.E. TenBrink, "Heterocyclic Chemistry: Benzoyl Peroxide Oxidation of Pyrimidines," Synthesis, 1975, 443.
76. J.M. McCall and R.E. TenBrink, "Heterocyclic N-oxide Reduction by Titanium Trichloride," Synthesis, 1975, 3398.
77. J.M. McCall, "Liquid-Liquid Partition Coefficients by High Pressure Liquid Chromatography," J. Med. Chem. 18, 549 (1975).
78. Zimmerman, Howard E.; Juers, Daniel; McCall, John M.; Schroeder, Barbara. "Slither motion of divalent carbon on pi systems in photochemical rearrangements. Exploratory and mechanistic organic photochemistry. LXIV". J. Amer. Chem. Soc. (1971), 93(15), 3662-74.
79. Zimmerman, Howard Elliot; Juers, Daniel F.; McCall, John M.; Schroeder, Barbara. "Walk processes in photochemical molecular rearrangements. General photochemical transformation. Mechanistic and exploratory organic photochemistry. LVII." J. Amer. Chem. Soc. (1970).
80. Zimmerman, Howard E.; Hackett, Peter; Juers, Daniel F.; McCall, John M.; Schroeder, Barbara. "Competitive photochemical pathways in the di-pi-methane rearrangement. Exploratory and mechanistic organic photochemistry. LXIII". J. Amer. Chem. Soc. (1971), 93(15), 3653-62.

Patents

1. John M McCall and Eric R. Calderon-Ortiz, "Heterocyclic Inhibitors of Rho GTPases for the treatment of disease. Filed 7/2/2020.US App # 63/047,463. Owner: MBQ Pharma
 - 2-11. John M McCall, Eric Hoffman, Kanneboyina Nagaraju, Jesse Damsker. Non-hormonal steroid modulators of NFkB for treatment of disease: US 8,207,151. Arthritis; US 8,334,279. Methods of treating muscular dystrophy; US 8,673,887. Methods of treating Crohn's disease, colitis, and inflammatory bowel disease; US 9,434,758. treatment of MS; US 9,649,320. treatment of COPD and asthma; US 10,206,933 atherosclerosis, hypercholesterolemia, chronic heart failure, ischemia/reperfusion, angina pectoris, and myocarditis; US10,206,833 formulation claims; US10,464,967 astracytomas including glioblastomas; 10,857,161 oral suspensions.
 12. Amy E. TAPPER, Cassandra CELATKA, Arthur ROMERO, John M. MCCALL, Toni CHANCELLOR, He ZHAO, Betina BIOLATTO, Jian-Xie CHEN, Elisabeth BROT, Peter Michels, Venkat Chari, Ian
-

Cotteril. Compositions and methods for producing stereoisomerically pure aminocyclopropanes. PCT/US2018/047192. Filed Aug 16, 2018

13. Mark Joseph Tebbe, Holly Victoria A, Craig Avery, Steven Mark Bromidge, Mark KERRY, Adrian Kotei Kotey, Nathaniel J. Monck, Mirco Meniconi, Mark Peter Ridgill, Heather Tye, Eddine Saiah, Kai Peter Johnsson, Katarzyna Irena Gorska, Hairuo Peng, John Michael McCall, Heteroary derivatives as sepiapterin reductase inhibitors, PCT/US2016/0546p57, 9/30/2015 priority.
 14. DL Romero, JM McCall, JBlitzer. Inhibitors of Dihydroceramide Desaturase for Treating Disease. Provisional 12/13/2016. PCT 12/13/2016
 15. BL Eriksen, MGustafsson, CHougaard, TAJacobsen, MJefson, GFKeaney, JKlein, JSLarsen, JALow, JMMccall. Potassium Channel Modulators, PCT/US2017/035662 filed June 2, 2017
 16. Martin Jefson, Janus Larsen, John Lowe, John McCall. Potassium Channel Modulators. US Provisional filing. Filed 6/9/2016.
 17. Hugh Rienhoff, Michael Clare, John McCall, Cassandra Celatka. KDM1a Inhibitors for the Treatment of Disease. PCT application #15/043,121. Filed 2/12/2016
 18. Mark Parnell, Donna Romero and John McCall. MCT4 Inhibitors for Treating Disease. Provisional Application No 62/174/685. Filed 6/12/2015. PCT filed 6/12/2016.
 19. Janus S. Larsen, Martin Jefson, John Lowee, John McCall, Magnus Gustafson, Birgitte Eriksen. Potassium Channel Modulators. Provisional filed 5/28/2015. Ataxion.
 20. modulators of NFkB for treatment of disease. WO2013/082253. Additional diseases claimed.
 21. Hugh Y. Rienhoff, John M. McCall, Mike Clare. KDM1A Inhibitors for the Treatment of Disease, - provisional application filed on 3/18/2014 (Scaffold 3). US case eventually filed in the US on 2/5/2016.
 22. Hugh Y. Rienhoff, John M. McCall, Mike Clare. KDM1A Inhibitors for the Treatment of Disease, - provisional application filed on 3/18/2014 (Scaffold 2)
 23. Hugh Y. Rienhoff, John M. McCall, Mike Clare. KDM1A Inhibitors for the Treatment of Disease, Non-provisional application. filed 3/11/2014 US and PCT (Scaffold 1)
 24. Donna Romero and John McCall, Heterocyclic compounds for the Inhibition of PASK. Tetrahydroquinolines. WO 2012/094462. PCT/US2012/020281. Publication date 8/30/2012. Issued US 201202205898A1
 25. John McCall with Donna Romero, Bob Kelly, and Mike Clare. Heterocyclic compounds for the Inhibition of PASK. Provisional filings March 3, 2011: US and PCT applications filed. PCT/US10/47736, US 12/874,967.
 - a. Serial # 61/449,009 US. Aryl Variants
 - b. Serial #61/449,020 US. Amine Variants
 - c. Serial #61/448,533 US. Misc Compounds
 - d. Serial #61/448,550 US. Prodrugs
 - e. Serial #61/448,552 US. Derivatives
 26. John M. McCall and Hugh Y Rienhoff, "Prodrugs of Desazadesferrothiocin Polyether Analogues as Metal Chelation Agents, Filed 7/26/2010 PCT app#12/843,483 and USP.
-

27. John McCall, Nagaraju Kanneboyina, Eric Hoffman. Non-hormonal steroid modulators of NFkB for treatment of disease. PCT/US09/45489, May 28, 2009. Also filed US 12/473.921
 28. John McCall, Jill Heemskerk, Keith Barnes, Graham Johnson, Dave Fairfax, Matthew Johnson. . Compounds for the treatment of Spinal Muscular Atrophy and Other Uses. WO 2007/109211,
 29. Jill Heemskerk, J.M. McCall, K. Barnes. Isoindoline compounds for the treatment of spinal muscular atrophy and other uses. PCT/US2008077936,. Filed in US and PCT on March 26, 2010 as application no. 12/680,285. WO 2009/042907
 30. J.M.McCall. Prasad Raje, Rajendrakumar Ruddy Gadikota, Jian-Xie Chen, Olga V. Lapina, Synthesis of Chirally Purified Substituted Benzothiazole Diamines. US priority date 3/14/2007. Filed PCT and US. US 13/973,987. Pub US 2014/0100372A1.
 31. J.M.McCall. Reboxetine for Treatment Obsessive Compulsive Disorders and Panic Disorder, U.S. 6,391,876. May 21, 2002
-
32. J.M. McCall, DEAyer, EJJacobsen, FJVanDoornik, JRPalmer, HAKarnes. Imidazolylpiperazinyl Steroids, US 5,506,354. April 9, 1996.
 33. J.M. McCall, Pyrazinylpiperazinyl Steroids, US 5,382,661, Jan. 17, 1995.
 34. J.M. McCall, E.J. Jacobsen, F.J. VanDoornik, Phenylpiperazinyl Steroids, US 5,380,839., January 10, 1995.
 35. J.M. McCall et.al., Pyrazinylpiperazinyl steroids, US 5,382,661, January 17, 1995
 36. J.M. McCall, E.J. Jacobsen, F.J. VanDoornik, J.R. Palmer, Piperazine Compounds as Neuroprotectants, US 5,322,943, June 21, 1994.
 37. J.M. McCall, E.J.J acobsen, F.J. VanDoornik, J.R. Palmer, "Pharmaceutically Active Amines", US 5,120,843, June 9, 1992.
 38. J.M. McCall, E.J. Jacobsen, F.J. VanDoornik, J.R. Palmer, "Amines Useful in Producing Pharmaceutically Active CNS Compounds", US 5,099,019, March 24, 1992.
 39. J.M. McCall, E.J. Jacobsen, F.J. VanDoornik, J.R. Palmer, "Pharmaceutically Active Primidinylpiperazinyl Steroids" , US 5,175,281 with 23 claims (protects tirilazad mesylate). December 29, 1992.
 40. J.M. McCall and E.J. Jacobsen, Aminosteroids, US 5,099,019.
 41. J.M. McCall, D.E. Ayer, E.J. Jacobsen, J.R. Palmer, H.A. Karnes, "Triazinylpiperazinyl amine intermediates", US 5,268,477, December 7, 1993.
 42. J.M. McCall, J.M. Braughler, E.D. Hall, W. Wierenga, "11- β -Hydroxy Steroid Distors", US 4,948, 533, August 14, 1990.
 43. J.M. McCall, J.M. Braughler, E.D. Hall, W. Wierenga, J. Folkman, "Inhibition of Angiogenesis involving the Coadministration of Steroids with Heparin or Heparin Fragments", US 4,771,042, September 13, 1988.
 44. J.M. McCall, "Isochromans", US 4,711,960, December 8, 1987.
 45. J.M. McCall, "1H-2-Benzopyran-1-yl Alkyl on 1-(Isochroman-1-yl)Alkyl Piperazines," U.S. 4,577,021, March 18, 1986.
 46. J.M. McCall and R.A. Lahti, "N-(2-Amino-cycloalkenyl)benzeneacetamide and -benzamide analgesics and tritiated kappa agonists therefrom," U.S.-4,560,767, December 24, 1985.
 47. J.M. McCall, "Isochromans, etc." U.S. 4,556,656, December 3, 1985.
 48. J.M. McCall, "N, 1-Dicyanoacetamidines, inters for triaminopyrimidines - with hypotensive activity," U.S. 3,910,928-A, June 9, 1985.

49. J.M. McCall, "Isochromans," U.S. 4,487,774, December 11, 1984.
50. M.J. DeGeeter, J.M. McCall. and Dirk L. Teagarden, "Animal Feed and Process," U.S. 4,393,065, July 12, 1983.
51. J.M. McCall, "Tetrahydrobenzopyran Derivatives," U.S. 4,329,459, May 11, 1982.
52. M.J. DeGeeter and J.M. McCall, "Animal Feed and Process," U.S. 4,315,930, February 16, 1982.
53. M.J. DeGeeter and J.M. McCall, "Animal Feed and Process, U.S. 4,316,901, February 23, 1982.
54. J.M. McCall, "Isothiochromans," U.S. 4,312,868, January 26, 1982.
55. M.J. DeGeeter and J.M. McCall, "Animal Feed and Process," U.S. 4,308,271, December 29, 1981.
56. M.J. DeGeeter and J.M. McCall, "Animal Feed and Process," U.S. 4,307,093, December 22, 1981.
57. J.M. McCall, "Sulfooxyprymidinium, Pyridinium and Triazinium Hydroxide Inner Salts," U.S. 4,287,338, October 1, 1981.
58. J.M. McCall and M.J. DeGeeter, "Animal Feed and Process," U.S. 4,282,228, August 14, 1981.
59. J.M. McCall, "2-Benzothiepins and Compositions and Methods of Use," U.S. 4,251,526, February 17, 1981.
60. J.M. McCall, "Methods of Treating Psychosis," U.S. 4,250,175, February 10, 1981.
61. J.M. McCall, "Methods of Treating Psychosis," U.S. 4,250,181, February 10, 1981.
62. J.M. McCall, "Methods of Treating Psychosis," U.S. 4,247,553, January 27, 1981.
63. J.M. McCall, "Isochroman," U.S. 4,181,665, January 1, 1980.
64. J.M. McCall, "Benzothiepins," U.S. 4,207,239, June 10, 1980.
65. J.M. McCall, "Isothiochromans," U.S. 4,206,123, June 3, 1980.
66. J.M. McCall, "Methods of Treating Psychosis," U.S. 4,179,510, December 18, 1979.
67. J.M. McCall, "Antihypertensive 4-Aminoquinolines," U.S. 4,167,567, September 11, 1979.
68. J.M. McCall, "7-Trifluoromethyl-4-Aminoquinolines," U.S. 4,166,853, September 4, 1979.
69. J.M. McCall and R.E. TenBrink, "1-Alkoxyethanol Isochromans, Isothio-chromans, 2-Benzoxepines, and 2-Benzothiepins," U.S. 4,166,062, August 28, 1979.
70. J.M. McCall, "Antihypertensive 4-Aminoquinolines," U.S. 4,159,331, June 26, 1979.
71. J.M. McCall, "2-Benzoxepines," U.S. 4,153,612, May 8, 1979.
72. J.M. McCall, "Piperazino Methyl Phenylaminoquinolines," U.S. 4,140,775, February 20, 1979.
73. J.M. McCall and J.J. Ursprung, "N,2-Dicyanoacetimidates," U.S. 4,032,559, June 28, 1977.
74. J.M. McCall and J.J. Ursprung, "3-(Cyanimino)-Propionitriles," U.S. Patent 3,910,928, October 7, 1975.

PATENTS (search results)

id	title	inventor/author	priority date	grant date
US-4771042-A	Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments	John M. Braughler, Edward D. Hall, John M. McCall, Wendell Wierenga, Judah Folkman	11/25/1985	9/13/1988
US-5120843-A	Pharmaceutically active amines	John M. McCall, Donald E. Ayer, E. Jon Jacobsen, Frederick J. VanDoornik, John R. Palmer	4/27/1987	6/9/1992
US-5175281-A	Pharmaceutically active pyrimidinylpiperazinylsteroids	John M. McCall, Donald E. Ayer, E. Jonathan Jacobsen, Frederick J. VanDoornik, John R. Palmer, Harold A. Karnes	9/12/1985	12/29/1992
US-4167567-A	Antihypertensive 4-aminoquinolines	John M. McCall	5/5/1978	9/11/1979
US-4159331-A	Antihypertensive 4-aminoquinolines	John M. McCall	5/5/1978	6/26/1979
US-5380839-A	Phenylpiperazinyl steroids	John M. McCall, E. Jon Jacobsen, Frederick J. VanDoornik	9/12/1985	1/10/1995
WO-8808424-A1	Pharmaceutically active amines	John M. McCall, Donald E. Ayer, E. Jon Jacobsen, Frederick J. Van Doornik, John R. Palmer	4/27/1987	
US-4329459-A	Tetrahydrobenzopyran derivatives	John M. McCall	5/5/1980	5/11/1982
US-4166853-A	Antihypertensive 7-trifluoromethyl-4-aminoquinolones	John M. McCall	5/5/1978	9/4/1979
US-4287338-A	Sulfooxy-pyrimidinium, -pyridinium, and -triazinium hydroxide inner salts	John M. McCall	3/10/1980	9/1/1981
EP-0263213-A1	C20 Through C26 amino steroids	John M. McCall, Donald E. Ayer, E. Jon Jacobsen, Frederick J. Van Doorick, John R. Palmer, Harold A. Karnes	10/9/1986	
US-4179510-A	Methods of treating psychosis	John M. McCall	10/31/1977	12/18/1979
US-4153612-A	2-Benzoxepins	John M. McCall	10/31/1977	5/8/1979
US-3910928-A	3-(Cyanimino)-propionitriles	John M. McCall, Joseph J. Ursprung	4/26/1974	10/7/1975
US-4247553-A	Methods of treating psychosis	John M. McCall	10/31/1977	1/27/1981
US-4948533-A	11a-hydroxy steroid diester	John M. Braughler, Edward D. Hall, Wendell Wierenga, John M. McCall	3/28/1984	8/14/1990
US-5268477-A	Triazinylpiperazinyl amine intermediates	John M. McCall, Donald E. Ayer, E. Jon Jacobsen, Frederick J. VanDoornik, John R. Palmer, Harold A. Karnes	9/12/1985	12/7/1993
US-4140775-A	Piperazino methyl phenyl aminoquinolines	John M. McCall	5/5/1978	2/20/1979
US-5099019-A	Amines useful in producing pharmaceutically active CNS compounds	John M. McCall, Donald E. Ayer, E. Jonathan Jacobsen, Frederick J. VanDoornik, John R. Palmer, Harold A. Karnes	9/12/1985	3/24/1992
US-4032559-A	N,2-dicyanoacetimidates	John M. McCall, Joseph J. Ursprung	7/28/1975	6/28/1977
US-5322943-A	Piperazine compounds which are substituted	John M. McCall, E. Jonathan Jacobsen, Frederick J. VanDoornik, John R. Palmer	9/12/1985	6/21/1994
US-4393065-A	Animal feed and process	Melvin J. DeGeeter, John M. McCall, Dirk L. Teagarden	6/23/1980	7/12/1983
US-4556656-A	2-Benzoxepins	John M. McCall	10/23/1978	12/3/1985
US-4207239-A	Benzothiepins	John M. McCall	10/31/1977	6/10/1980
US-4181665-A	Isochroman	John M. McCall	10/31/1977	1/1/1980
US-4312868-A	Isothiochromans	John M. McCall	10/31/1977	1/26/1982
US-4598088-A	2-pyrrolyl-cycloalkyl-amide analgesics	Jacob Szmuskovicz, John M. McCall, Lester J. Kaplan, Moses W. McMillan	5/18/1983	7/1/1986
US-4487774-A	Isochromans	John M. McCall	10/31/1977	12/11/1984
US-4308271-A	Animal feed and process	Melvin J. DeGeeter, John M. McCall	6/23/1980	12/29/1981
US-4250181-A	Methods of treating psychosis	John M. McCall	10/31/1977	2/10/1981
US-4166062-A	1-alkoxyethanol-isochromans, -isothiochromans, -2-benzoxepins, and -2-benzothiepins	John M. McCall, Ruth E. TenBrink	7/21/1978	8/28/1979

US-4352805-A	Methods of treating psychosis	John M. McCall	9/5/1979	10/5/1982
US-4711960-A	Isochromans	John M. McCall	10/31/1977	12/8/1987
US-4577021-A	1H-2-Benzopyran-1-yl alkyl on 1-(isochroman-1-yl)alkyl piperazines	John M. McCall	10/31/1977	3/18/1986
US-4282228-A	Animal feed and process	Melvin J. DeGeeter, John M. McCall	6/23/1980	8/4/1981
US-4307093-A	Animal feed and process	Melvin J. DeGeeter, John M. McCall	6/23/1980	12/22/1981
US-RE35053-E	Amines useful in producing pharmaceutically active CNS compounds	John M. McCall, E. Jon Jacobsen	9/12/1985	10/10/1995
US-4315930-A	Animal feed and process	Melvin J. DeGeeter, John M. McCall	6/23/1980	2/16/1982
US-4316901-A	Animal feed and process	Melvin J. DeGeeter, John M. McCall	6/23/1980	2/23/1982
US-4560767-A	N-(2-amino-cycloalkenyl)benzeneacetamide and -benzamide analgesics and tritiated kappa agonists therefrom	John M. McCall, Robert A. Lahti	6/17/1983	12/24/1985
CA-1308707-C	20- and 21-amino steroids	John M. Mccall, Donald E. Ayer, Eric Jon Jacobsen, Frederick Jay Vandoornik, John R. Palmer	9/12/1985	10/13/1992
EP-0263208-A2	Antiarrhythmic use of aminocycloalkylamides	John M. Mccall, John R. Luderer, Paula F. Kane, J. Kenneth Gibson	6/7/1985	
DK-237587-D0	Amino-substituted steroids, pharmaceutically acceptable salts, hydrates and solvates thereof	John M Mccall, Donald Ayer, Jon E Jacobsen, Frederick J Van Doornik, John R Palmer, Harold A Karnes	9/12/1985	5/11/1987
WO-8605489-A1	Process for 4-amino quinolines	John M. Mccall	3/13/1985	
CA-2071000-A1	5-oxygenated-2,4,6-triaminopyrimidines	John M. Mccall, Eric J. Jacobsen	1/26/1990	
WO-8701706-A3	C20 through c26 amino steroids	Donald E Ayer, E Jon Jacobsen, Harold A Karnes, John M Mccall, John R Palmer, Doornik Frederick J Van	9/12/1985	
search URL:	https://patents.google.com/?inventor=John+M+McCall&assignee=Bioenergenix&patents=false&oq=John+M+McCall			
id	title	inventor/author	priority date	grant date
WO-2011028947-A2	Heterocyclic compounds for the inhibition of pask	John M. Mccall, John Mckearn, Donnal L. Romero, Michael Clair	9/3/2009	
US-2012277224-A1	Heterocyclic compounds for the inhibition of pask	John M. McCall, Robert C. Kelly, Donna L. Romero	4/26/2011	
US-2012225863-A1	Heterocyclic compounds for the inhibition of pask	John M. McCall, Donna L. Romero	3/2/2011	
US-8912188-B2	Substituted quinoxaline carboxylic acids for the inhibition of PASK	John M. McCall, Donna L. Romero, Robert C. Kelly	3/2/2011	12/16/2014
US-9073902-B2	Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK	John M. McCall, Donna L. Romero	1/5/2011	7/7/2015
US-2012225846-A1	Heterocyclic compounds for the inhibition of pask	John M. McCall, Donna L. Romero, Michael Clare	3/2/2011	
US-9370522-B2	Heterocyclic compounds for the inhibition of PASK	John M. McCall, Donna L. Romero, Michael Clare	3/19/2009	6/21/2016
search URL:	https://patents.google.com/?inventor=John+M+McCall&assignee=Albany+Molecular+Research%252c+Inc.&patents=false&oq=John+M+McCall			
id	title	inventor/author	priority date	grant date
WO-2007109211-A2	1-oxo-isindoline compounds for the treatment of spinal muscular atrophy and other uses	Jill Heemskerk, Keith D. Barnes, John M. Mccall, Graham Johnson, David Fairfax, Matthew Robert Johnson	3/17/2006	

WO-2009042907-A1	Isoindoline compounds for the treatment of spinal muscular atrophy and other uses	Jill E. Heemskerk, John M. McCall, Keith D. Barnes	9/27/2007	
WO-2012142459-A1	Isoindoline compounds for the treatment of spinal muscular atrophy and other uses	Keith D. Barnes, Jill E. Heemskerk, John William LIPPERT III, Nicholas James MAYHEW, John M. McCall	4/14/2011	
WO-2015021128-A1	Kdm1a inhibitors for the treatment of disease	John M. McCall, Jr. Hugh Young REINHOFF, Michael Clare	8/6/2013	
WO-2016130952-A1	Kdm1a inhibitors for the treatment of disease	Hugh Young Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper	2/12/2015	
WO-2018035249-A1	Compositions and methods for producing stereoisomerically pure aminocyclopropanes	Amy E. Tapper, Cassandra Celatka, Arthur Glenn Romero, John M. McCall, Toni Chancellor, He Zhao, Betina Biolatto, Jian-Xie Chen, Elisabeth C.A. BROT, Peter C. Michels, Venkat K. CHARI, Ian C. COTTERILL	8/16/2016	
WO-2018035259-A1	Methods and processes for the preparation of kdm1a inhibitors	Amy E. Tapper, Cassandra Celatka, Arthur Glenn Romero, John M. McCall, Toni Chancellor, Jian-Xie Chen, Xuemei Chen, He Zhao, Betina Biolatto, Elisabeth C.A. BROT, Zhihua Li, Xiaoming LIAO	8/16/2016	
WO-2018111904-A1	Heterocyclic inhibitors of mct4	Kenneth Mark PARNELL, John M. McCall, Donna Romero	12/12/2016	
EP-3307068-A1	Mct4 inhibitors for treating disease	Kenneth Mark PARNELL, John M. McCall	6/12/2015	
search URL:	https://patents.google.com/?inventor=John+M+McCall&assignee=Cadent+Therapeutics%252c+Inc.&patents=false&oq=John+M+McCall			
id	title	inventor/author	priority date	grant date
US-2017355708-A1	Potassium channel modulators	Martin R. Jefson, Gregg F. Keaney, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall	6/9/2016	
WO-2017210545-A1	Potassium channel modulators	Birgitte Langer ERIKSEN, Magnus Gustafsson, Charlotte Hougaard, Thomas Amos JACOBSEN, Martin R. Jefson, Jessica KLEIN, Janus Schreiber LARSEN, John A. Lowe, Iii, John M. McCall, Dorte STROË~BÃ+K, Nadia LybÃ,l VON SCHOUBYE, Gregg F. Keaney	6/2/2016	
US-2010087408-A1	NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE	John M. McCall, Eric Hoffman, Kanneboyina Nagaraju	5/28/2008	
US-2015011519-A1	Non-hormonal steroid modulators of nf-kappa beta for treatment of disease	John M. McCall, Eric Hoffman, Nagaraju (Raju) Kanneboyina, Jesse Damsker	11/29/2011	
US-9198921-B2	Non-hormonal steroid modulators of NF-Î±B for treatment of disease	John M. McCall, Eric Hoffman, Kanneboyina Nagaraju	4/5/2010	12/1/2015
US-2016375037-A1	Non-hormonal steroid modulators of nf-kappa beta for treatment of disease	John M. McCall, Eric Hoffman, Kanneboyina Nagaraju, Jesse Damsker	6/29/2015	
WO-2011127048-A2	NON-HORMONAL STEROID MODULATORS OF NF-Ã,B FOR TREATMENT OF DISEASE	John M. McCall, Eric Hoffman, Kanneboyina Nagaraju	4/5/2010	
US-2010087408-A1	NON-HORMONAL STEROID MODULATORS OF NF-kB FOR TREATMENT OF DISEASE	John M. McCall, Eric Hoffman, Kanneboyina Nagaraju	5/28/2008	
WO-2007109211-A2	1-oxo-isindoline compounds for the treatment of spinal muscular atrophy and other uses	Jill Heemskerk, Keith D. Barnes, John M. McCall, Graham Johnson, David Fairfax, Matthew Robert Johnson	3/17/2006	
WO-2009042907-A1	Isoindoline compounds for the treatment of spinal muscular atrophy and other uses	Jill E. Heemskerk, John M. McCall, Keith D. Barnes	9/27/2007	

